We no longer support this browser. Using a supported browser will provide a better experience.

Please update your browser.

Close browser message

40th Annual J.P. Morgan
Health Care Conference
January 10 – 13, 2022 | Virtual

The 40th Annual Health Care Conference will take place virtually on January 10-13, 2022.

This premier conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.

Keynotes

Jamie Dimon
Chairman and Chief Executive Officer,
JPMorgan Chase & Co.
Full Bio
Jessica Fye
Managing Director, Equity Research - Biotech,
J.P. Morgan
Full Bio
Catherine Pollard
Director of Tech Policy, NHSX
Full Bio
Chris Wigley
Chief Executive Officer, Genomics England
Full Bio
Lord David Prior
Chair, NHS England
Full Bio
Dan Mendelson
CEO, Morgan Health
Full Bio
Dr. Mark McClellan
MD, PhD
Full Bio
Andrew Bindman
MD, EVP and Chief Medical Officer,
Kaiser Permanente
Full Bio
Chiquita Brooks-LaSure
Administrator,
Centers for Medicare and Medicaid Services
Full Bio
Bertha Coombs
CNBC Reporter
Full Bio
Jean Hynes
CEO, Wellington Management
Full Bio
Saira Malik
CFA CIO, Head of Global Equities
Full Bio
Lucy DeStefano
Global Head of Trading and Systematic Strategies
Full Bio
Julie Murphy
Health Care Sector Specialist on the J.P. Morgan Trading Desk
Full Bio

Insights

Jess Fye

Senior Analyst, U.S. Biotechnology J.P. Morgan Research

Video Play Button
Video Play Button

Jess Fye

Senior Analyst, U.S. Biotechnology J.P. Morgan Research

Jess Fye: As we think about the biotech industry and how it adapted to COVID-19, one of the key themes that comes to mind is the real resilience of these companies in changing their commercial model in response to the pandemic. So when the pandemic broke out, one of the things you couldn't do was interact with a physician face to face. This is especially important when it's a drug that physicians aren't already familiar with. These companies quickly adopted more virtual means of educating physicians around their product. I think some of these strategies that the company has developed in response to COVID are gonna remain in 2022 and beyond. They've just found multiple effective ways to engage with doctors that are, that are actually working. The biotech sector has underperformed this year. There could be a variety of explanations for that. The sector did see a lot of outperformance the prior year, benefiting from maybe a halo effect of the industry tackling COVID. As a result, we really think you need to apply a selective approach heading into next year to sift through the real winners and the companies with the best innovation. M&A in the biotech sector is always tough to call when it comes to timing, I think investors would always want to see more rather than less. You contrast that with a very kind of high access to capital right now. You may not always see that acquisition because the companies are able to afford to continue to invest in development on their own. We do still expect a high level of IPOs and new company formation. The access to capital for these companies has been somewhat unprecedented. Heading into 2022, we're seeing some major innovations in the industry. Most people who have followed this industry would say the rate of acceleration has really increased over of the past 10 years and the past 10 years before that. Some of the key themes would be cell therapy and gene therapy. Those really represent new toolboxes to tackle some of these diseases and you're seeing a lot of investment behind those approaches. But we're also seeing real advances in more traditional disease areas that are leveraging our better understanding of the genetic underpinnings of some of these diseases. The rate of innovation shows no signs of slowing and lots of signs of picking up, and I think that makes it a really exciting industry to cover.

Chris Schott

Senior Analyst, U.S Major and Specialist Pharmaceuticals J.P. Morgan Research

Video Play Button
Video Play Button

Chris Schott

Senior Analyst, U.S Major and Specialist Pharmaceutical

Chris Schott: Looking at the current situation with the pandemic, I know there’s a lot of concerns around the new variants and I think that has some real implications as we think about the vaccines and therapeutics as well as the longer-term implications for how the sector’s approaching drug development. First of all: vaccine capacity. There are literally billions of additional doses of the vaccine that will be available in 2022 versus what was available in 21. And that’s gonna allow a much greater percentage of the world’s population to be vaccinated. The second thing are boosters. As new variants emerge, you create a new vaccine. And what’s great about the new technology being used is you can develop these in three to four months. And then finally, and I think really underappreciated, are the oral antivirals. These are products that you'll literally take five days worth of pills. You reduce hospitalization rates by 90 percent, death rates by 100 percent. I think it's a game changer in terms of dealing with the pandemic. If I think about broader takeaways to the pandemic, I think we're gonna see a much more efficient, much more focused pharmaceutical sector. I'm kind of amazed at how much the industry was able to produce in only 18 months. Now applying that to other therapeutic areas, I think we can see faster study enrollment, more creative study design, and that's gonna bring drugs to market much faster in some situations than we've ever seen previously. Heading into 2022, the pharma sector right now trades at an all time low versus the S&P 500. And I think there's really two issues that are overhanging the group: one, drug price reform, and we'll get some clarity on that with the infrastructure bill. The second is this longer term patent cliff. We're much more optimistic than the street about the ability for the industry to navigate through this. If I think about the last patent cliff, it was 2010 through 12, it really was a cliff. This time around, we've got internal pipelines that are looking great, we've got a lot more external opportunities to access innovation than we had in the past. And we think about this more as a slow down in growth, as compared to a cliff. We can see an acceleration of M&A going forward. We think M&A increasingly is focused on innovation, and it leads you to more pharma-biotech collaborations and consolidation, again versus the large pharma consolidation of the past. I see innovation as really a core theme for the sector. We're still at levels that are two times what they were 5 or 10 years ago. On Alzheimer's, we had the first disease modifying Alzheimer's drug approved in 2021; it's a very controversial product. Going to 22 and 23, there’s at least three additional products that we think really build upon this approval. And then finally on obesity, two diabetes products are actually associated with profound weight loss, and we think this creates a whole new category where we actually medicalize obesity. It can be something that insurers actually pay for and really encourage what that means for both patients with these conditions as well as the industry in terms of having a lot more new product flow.

FAQs

The J.P. Morgan Health Care Conference is for clients of the firm, by invitation only. Please reach out to your J.P. Morgan representative to inquire about an invitation.

Some company presentations will be available on their individual websites.

The agenda is made available only to confirmed attendees.

Yes; there are a limited number of press passes for the event.

Unless otherwise specified, conference webinars are on-the-record and open to registered members of the press.

Related Insights

Inperson Header
in-person @jpmorgan

Steve Gleason, former NFL player for the New Orleans Saints and founder of the Team Gleason Foundation, shares the importance of assistive technology.

Learn More
health care outlook Header
Innovation in Pharma

J.P. Morgan's senior pharmaceuticals analyst, Chris Schott, is optimistic about innovation in pharma.

Learn More
Future is Electric image
Global Research Reports

J.P. Morgan's Research team leverages cutting-edge technologies and innovative tools to bring clients industry-leading analysis and investment advice.

Learn More